4588 JPX Week ended 07 Aug 2026

Weekly Investor Report

Oncolys BioPharma Inc. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 2,848 JPY
6.9% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 12.9% above the Trend Line and sits at 72.6% of its 52-week range. The latest completed week returned 6.9%, after a 10.6% four-week move. The latest news-sentiment score is 50/100.

Setup score 63 out of 100
Latest Close 2,848 JPY 7 Aug 2026
1W Return 6.9% latest completed week
4W Return 10.6% short-term follow-through
12W Return 6.3% quarterly tape
Trend Breadth 100.0% 52 of 52 weeks active
Volume Ratio 1.1x vs 13-week average
What is working
  • The trend backdrop is active with a 52-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Activity pressure is negative, which weakens the current setup.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 6.9% Latest completed week; four-week move 10.6%. Indicator stack 100/33 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 50/100 2 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 12.9% above the Trend Line and sits at 72.6% of its 52-week range. The latest completed week returned 6.9%, after a 10.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5912-week average 0.76

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.59Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 10.6% over four weeks, 6.3% over 12 weeks, and 373.1% over one year. The current trend has remained active for 52 consecutive weeks.

Performance by holding period

1W6.9%
4W10.6%
12W6.3%
26W52.1%
52W373.1%
Active trend streak52 weeks
Active weeks in one year52
Trend breadth100.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.85Latest activity-pressure read.
Pressure change-22.4%Four-week change in activity pressure.
Leadership36.93Latest relative-leadership reading.
RS change40.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

A published fundamentals and factor snapshot is not available for this company.

Open full factor analysis

No published fundamental snapshot is available for this company.

05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 2 relevant articles.

0 positive · 2 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-22.9%Distance below the 52-week high.
13-week volatility5.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+30.3%Week of 13 Feb.
Worst week-16.9%Week of 20 Mar.
Latest week+6.9%Week of 7 Aug.

Shape of recent returns

Strong gains14
Modest gains0
Flat weeks0
Modest losses4
Sharp losses8
Recent vol5.8%13-week weekly-return volatility.
Base vol12.5%52-week weekly-return volatility.
Up/down split30/21Count of positive and negative weeks in the 52-week window.
Average skew12.3% / -8.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape64/100

Trend, activity pressure, participation, and risk combine to a 64/100 tape read.

 Indicator analysis63/100

Latest 12-week confirmation: trend 12/12, activity pressure 0/12, relative leadership 12/12.

Activity pressure 0.59; No reversal markers Factors50/100

No published factor snapshot is available yet.

 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 2 relevant articles.

Japan backs Oncolys virus therapy for esophageal cancer Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20262,848 JPY6.9%2,522 JPY1,011 JPY-0.8536.934.6MOn
31 Jul 20262,665 JPY7.9%2,478 JPY997.0 JPY-1.0032.952.4MOn
24 Jul 20262,469 JPY5.0%2,435 JPY983.3 JPY-0.9424.791.6MOn
17 Jul 20262,351 JPY-8.7%2,389 JPY970.9 JPY-0.7521.522.7MOn
10 Jul 20262,575 JPY-3.9%2,340 JPY959.2 JPY-0.7026.242.9MOn
3 Jul 20262,680 JPY-1.9%2,289 JPY946.2 JPY-0.7930.96772.5KOn
26 Jun 20262,733 JPY5.5%2,231 JPY932.9 JPY-0.8536.37627.1KOn
19 Jun 20262,591 JPY5.0%2,179 JPY919.7 JPY-0.7927.88839.2KOn
12 Jun 20262,467 JPY-5.6%2,125 JPY907.6 JPY-0.5533.241.5MOn
5 Jun 20262,614 JPY-5.5%2,078 JPY895.9 JPY-0.3442.041.4MOn
29 May 20262,765 JPY-1.1%2,019 JPY883.4 JPY-0.1953.1411.5MOn
22 May 20262,797 JPY4.4%1,952 JPY869.5 JPY-0.2565.1713.3MOn
15 May 20262,680 JPY-8.2%1,882 JPY855.5 JPY-0.2266.878.5MOn
8 May 20262,918 JPY7.4%1,816 JPY842.2 JPY-0.1581.871.2MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.